For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. Rational Design of sub-100 nm Polystyrene Particles with a Low Coefficient of Variation in Size

    SBC: Tetramer Technologies,L.L.C.            Topic: NA

    During this Phase II SBIR development program, Tetramer Technologies will develop highlymonodisperse 100-nm and sub-100-nm diameter nanoparticles for use as latex size standards. Highlymonodisperse nanoparticle latexes are needed for improved calibration of electron microscopes, lightscatteringparticle sizing instruments, atomic force microscopes, and particle counters/contamination monitors used ...

    SBIR Phase II 2018 Department of CommerceNational Institute of Standards and Technology
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human Services
  3. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc.            Topic: 102

    PROJECT SUMMARY GlioblastomaGBMis an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomideTMZEfforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brainIn contrastsensitizing GBM to TMZ is an appealing strategy because TMZ has excelle ...

    SBIR Phase II 2018 Department of Health and Human Services
  4. Development of new anti-epilepsy treatments targeting cellular energetics through mitochondrial modulation with optimal pharmacokinetics and toxicity profiles

    SBC: Neuroene Therapeutics, LLC            Topic: 105

    Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available antiepileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilepsy and do ...

    SBIR Phase II 2018 Department of Health and Human Services
  5. he 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production

    SBC: KIYATEC, LLC            Topic: NIBIB

    Project Summary Abstract The transfusion of platelets is a major component of the treatment of cancer patients undergoing chemotherapy and or bone marrow transplantstrauma patientssepsisand battlefield injuriesHoweverdue to a complete reliance upon donors as the only current approved source of plateletsand the strictshort shelf life and storage conditions of donorderived plateletscurrent supplies ...

    SBIR Phase II 2017 Department of Health and Human Services
  6. New Approaches to Improved PEM Electrolyzer Ion Exchange Membranes

    SBC: Tetramer Technologies,L.L.C.            Topic: 13a

    This technology will significantly lower the energy cost for production of industrial gases, transportation fuels, and renewable energy and will aid in securing the US microgrid through improved backup power energy. This knowledge based commercial enterprise will not only create > 100 high paying jobs that will stay in the US, but also demonstrate expanded American leadership in high technology pr ...

    SBIR Phase II 2017 Department of Energy
  7. A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis

    SBC: Regranion, LLC            Topic: NIAMS

    PROJECT SUMMARY Psoriasis is a chronic inflammatory skin disease affecting approximatelymillion Americans that can become debilitating and severely impact quality of lifeWhile an estimatedof patients suffer moderate to severe disease forms that require systemic therapy with immune suppressants and ultraviolet phototherapythe majorityof patients exhibit milder symptomsFor these patientstopical agen ...

    SBIR Phase II 2017 Department of Health and Human Services
  8. An HXYZ-g HR-Fast-MAS probe for Dramatically Improved Biomolecular Structure Determinations

    SBC: DOTY SCIENTIFIC, INC.            Topic: 400

    An HXYZ g HR Fast MAS probe for Dramatically Improved Biomolecular Structure Determinations AbstractLiquid state NMR spectroscopy is arguably one of the best tools for structure determination for soluble proteinsThe method provides atomic resolution for modest molecular weight proteins and or their complexesThe method begins to have difficulty when the molecular weight of the system causes slow mo ...

    SBIR Phase II 2017 Department of Health and Human Services
  9. SBIR Phase II: High-capacity Multimodal Anion-exchange Membranes for Purification of Biologics

    SBC: Purilogics, LLC            Topic: 400

    Project Summary This SBIR Phase II project will address the need for column chromatography products that can simplify the purification process for therapeutic biologics and increase purification speedThe rapid pace of biologics developmentdriven in part by growth of emerging markets such as personalized medicinehas increased the demand for affordable and fastsmall batch production runs in multi pr ...

    SBIR Phase II 2017 Department of Health and Human Services
  10. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 100

    ABSTRACTWhile acute stroke is a leading cause of human death and disability in the United Statesunfortunatelyclinical therapies for stroke are limited and unsatisfactoryThe overwhelming failures of stroke treatments in clinical trials strongly indicate thatto battle this multifaceted brain disordernovel strategies that target multiple cell types and afford different mechanisms of protection are ne ...

    SBIR Phase II 2017 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government